COMP <GO>
TGTX vs CYTK // NET PROFIT MARGIN
TG Therapeutics Inc. (NASDAQ) VS. Cytokinetics Incorporated (NASDAQ) • 15-METRIC TALLY: TGTX 9
— CYTK 1
▲ NET PROFIT MARGIN LEADER: TGTX
LAST: $59.95 (-2.01%) • MKT CAP: $9.36B
net-margins
68.00%
LAST: $62.03 (-1.52%) • MKT CAP: $8.76B
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TGTX VS. CYTK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TGTX | CYTK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.00% | -35.00% | +47.00 | TGTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.28% | -6.08% | +5.80 | TGTX | /fcf-yield <GO> |
| Operating Margin | 20.00% | -60.00% | +80.00 | TGTX | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 68.00% | -60.00% | +128.00 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 87.30% | 180.00% | -92.70 | CYTK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.92 | 0.45 | +12.47 | TGTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | TGTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.7 | 46.0 | +18.70 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.87 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.7x | 31.0x | -14.30 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.36B | $8.76B | $607.7M | TGTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TGTX REV | CYTK REV | TGTX GROSS % | CYTK GROSS % | TGTX FCF | CYTK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | $88.0M | 83.7% | — | -$25.0M | -$534.8M |
| FY 2024 | $329.0M | $18.5M | 88.3% | — | -$40.6M | -$399.8M |
| FY 2023 | $233.7M | $7.5M | — | — | -$41.9M | -$414.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TGTX // BETA 0.87
CYTK // BETA 0.87